Studies of GLP-1 receptor agonists in women with PCOS have documented weight loss ranging from 8-15% over 6-12 months, along with improvements in testosterone levels, menstrual cycle regularity, and ovulatory function
The lawsuits name pharmaceutical companies responsible for manufacturing and marketing GLP-1 medications without adequate warnings: Novo Nordisk, the maker of Ozempic (for type 2 diabetes), Wegovy (for weight loss), and Rybelsus (oral semaglutide for diabetes) Eli Lilly, the maker of Trulicity (dulaglutide) and Mounjaro (tirzepatide), which are also GLP-1 receptor agonists associated with similar gastrointestinal risks These companies marketed their products heavily, particularly for weight loss, without fully disclosing the potential for severe and potentially permanent digestive complications
Your care team also provides personalized dosing guidance and support to help you maintain adherence and achieve your weight loss goals
As of early 2026, over 3,000 lawsuits are pending against the manufacturers of GLP-1 drugs
Positron emission tomography imaging in dementia